Githa Rahmayunita

Githa Rahmayunita

Auto-generated profile, based on publicly available information

Githa Rahmayunita

Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ISIrma Bernadette S Sitohang
Irma Bernadette S Sitohang
GRGitha Rahmayunita
Githa Rahmayunita
VHVashty Amanda Hosfiar
Vashty Amanda Hosfiar
SNShafira Ninditya
Shafira Ninditya
MAMaureen Augustin
Maureen Augustin

5 October 2020 in Medical Journal of Indonesia
Verified
Journal Article
Open access
PDF file
IDInne Arline Diana
Inne Arline Diana
SGSrie Prihianti Gondokaryono
Srie Prihianti Gondokaryono
TSTiti Lestari Sugito
Titi Lestari Sugito
MLMaya Devita Lokanata
Maya Devita Lokanata
TATriana Agustin
Triana Agustin
DYDanang Agung Yunaidi
Danang Agung Yunaidi
BACKGROUND Super-absorbent diaper is a disposable diaper with new technology which has a soft-airy structure, breathable sheet, and rich absorbent core. This study aimed to compare the safety and efficacy of super-absorbent diaper with standard absorbent diaper. METHODS A single-blinded, randomized, controlled, cross-over study was performed in 3–24 months babies. A safety study was performed in 113 babies without diaper rash (group A: super-absorbent to standard and B: standard to super-absorbent) and efficacy study in 59 babies with mild-to-moderate diaper rash (group C: super-absorbent to standard and D: standard to super-absorbent). Each group used super-absorbent or standard diaper for 2 weeks. Skin assessment scores (SAS) were recorded at baseline, week-2, and week-4. Non-parametric tests were used to analyze the data. RESULTS In the safety study, there was no significant increase of SAS in group A at week-2 and -4, but in group B there was a significant increase of SAS (1.9 to 4.1, p = 0.001) at week-2 with a significant reduction at week-4 (4.1 to 2.2, p<0.001). In the efficacy study, there was a reduction of SAS at week-2 in group C (p = 0.07) and D (p = 0.05). However, SAS increased in group C (6.4 to 8.3, p = 0.2) and decreased in group D (8.6 to 6.1, p = 0.13) at week-4. Super-absorbent diaper showed a significant reduction of SAS in the pubic areas (1.43 to 0.73, p<0.011). CONCLUSIONS The new super-absorbent diaper is safe to use and may have efficacy in the improvement of skin conditions and diaper rash, especially in the pubic areas.

10 March 2026 in Asia Pacific Allergy
Verified
Journal Article
Open access
GRGitha Rahmayunita
Githa Rahmayunita
PHPaulus Anthony Halim
Paulus Anthony Halim
DHDionisius Ivan Yonathan Halim
Dionisius Ivan Yonathan Halim
RARinadewi Astriningrum
Rinadewi Astriningrum
RRRahadi Rihatmadja
Rahadi Rihatmadja
TATriana Agustin
Triana Agustin
Generalized pustular psoriasis (GPP) is a rare, severe form of psoriasis that may be associated with monogenic autoinflammatory disorders such as deficiency of interleukin-36 receptor antagonist (DITRA). We report 2 Indonesian siblings with infantile-onset erythrodermic GPP caused by homozygous IL36RN c.115 + 6T>C mutations, representing the first genetically confirmed familial DITRA cases from Indonesia. The elder sister developed recurrent pustular flares from early infancy that progressed to chronic erythroderma with acrodermatitis continua of Hallopeau (ACH). The younger sibling presented at 8 months of age with widespread pustular eruptions and early ACH. Genetic testing confirmed homozygosity for the pathogenic variant in both siblings, while their parents and brother were heterozygous carriers. Both patients demonstrated hallmark features of DITRA, including early onset, acral pustulosis, and chronic relapsing disease. Conventional systemic therapies provided only partial control, highlighting therapeutic limitations in resource-limited settings where biologics such as secukinumab remain inaccessible. These cases add to the limited reports of DITRA from Southeast Asia and underscore the importance of genetic testing in early-onset GPP for accurate diagnosis, family counseling, and consideration of targeted therapy.